回顾性分析贝伐单抗联合化疗治疗复发性卵巢癌的临床疗效及安全性评价

发布时间：2018-04-29 06:39

  本文选题：贝伐单抗 + 化疗　； 参考：《中国临床药理学杂志》2015年15期

【摘要】：目的评价贝伐单抗联合化疗治疗复发性卵巢癌的临床疗效及安全性。方法回顾性分析我院收治的37例复发性卵巢癌患者的临床资料,所有患者接受至少2个周期的贝伐单抗联合化疗方案(7.5 mg·kg-1贝伐单抗+0.9%氯化钠250 m L静脉滴注60 min),并在化疗方案开始前1 h输注完毕。按实体肿瘤疗效评价标准(RECIST)和血清糖类癌症抗原125(CA125)标准分析患者的客观有效率,同时分析患者的生存时间及不良反应发生率。结果治疗后,患者的客观有效率为32.4%(RECIST标准)和43.2%(CA125标准)、中位无疾病进展生存时间为5.4个月。2例患者达到完全缓解,无疾病进展生存时间分别为10.0个月和11.2个月。血液学不良反应主要为Ⅰ~Ⅱ级中性粒细胞减少和血小板减少。非血液学不良反应主要为Ⅰ~Ⅱ级恶心呕吐,腹泻和高血压。结论贝伐单抗联合化疗治疗复发性卵巢癌的临床疗效确切,可作为复发性卵巢癌的备选治疗方案。
[Abstract]:Objective to evaluate the efficacy and safety of bevacizumab combined with chemotherapy in the treatment of recurrent ovarian cancer. Methods the clinical data of 37 patients with recurrent ovarian cancer in our hospital were retrospectively analyzed. All patients received at least 2 cycles of bevacizumab combined with 7.5 mg kg-1 bevacizumab 0.9% sodium chloride 250ml intravenously for 60 mins, and were infused 1 hour before the start of chemotherapy. The objective effective rate of patients was analyzed according to the criteria of solid tumor efficacy evaluation (RECIST) and serum carbohydrate cancer antigen 125 (CA125). The survival time and the incidence of adverse reactions were also analyzed. Results after treatment, the objective effective rate was 32.4%(RECIST standard and 43.2%(CA125 criterion. The median survival time of disease free progression was 5.4 months. The survival time of disease free progression was 10.0 and 11.2 months, respectively. Hematological adverse reactions were mainly grade 鈪，

本文编号：1818850